ABSTRACT: Although mortality after ST-segment elevation myocardial infarction (MI) is on the decline, the number of patients developing heart failure as a result of MI is on the rise. Apart from timely reperfusion by primary percutaneous coronary intervention, there is currently no established therapy for reducing MI size. Thus, new cardioprotective therapies are required to improve clinical outcomes after ST-segmentelevation MI. Cardiovascular magnetic resonance has emerged as an important imaging modality for assessing the efficacy of novel therapies for reducing MI size and preventing subsequent adverse left ventricular remodeling. The recent availability of multiparametric mapping cardiovascular magnetic resonance imaging has provided new insights into the pathophysiology underlying myocardial edema, microvascular obstruction, intramyocardial hemorrhage, and changes in the remote myocardial interstitial space after ST-segment-elevation MI. In this article, we provide an overview of the recent advances in cardiovascular magnetic resonance imaging in reperfused patients with ST-segment-elevation MI, discuss the controversies surrounding its use, and explore future applications of cardiovascular magnetic resonance in this setting. I mprovements in the treatment of patients with acute ST-segment-elevation myocardial infarction (STEMI) have led to a decline in mortality over the past 4 decades, 1 with 1-year cardiac mortality in patients with STEMI plateauing at ≈8%.
I
mprovements in the treatment of patients with acute ST-segment-elevation myocardial infarction (STEMI) have led to a decline in mortality over the past 4 decades, 1 with 1-year cardiac mortality in patients with STEMI plateauing at ≈8%. 2 However, morbidity caused by post-myocardial infarction (MI) heart failure remains significant and is on the rise. 3 The process of reperfusion itself can paradoxically induce further myocardial injury and cardiomyocyte death, a phenomenon called myocardial reperfusion injury. 4 There is currently no effective therapy for reducing myocardial reperfusion injury, despite a wealth of research in this field. This has been attributed partly to undertaking clinical studies despite the lack of reproducible and robust preclinical data, and the design of the clinical cardioprotection studies in terms of patient selection and inappropriate timing and mode of delivery of the cardioprotective agent. 5 Thus, the search continues for a novel and effective therapy for reducing MI size and preventing heart failure that can be administered as an adjunct to primary percutaneous coronary intervention (PPCI) after STEMI. Cardiovascular magnetic resonance (CMR) has emerged as an important imaging modality for assessing the cardioprotective efficacy of novel therapies for reducing MI size and preventing adverse left ventricle (LV) remodeling in reperfused patients with STEMI. 6, 7 It is currently the gold standard imaging modality for quantifying MI size 8 and is able to detect small subendocardial MI (as little as 1 g) 9 with good accuracy.
With the recent availability of native T1, T2, T2*, and postcontrast T1 mapping (to derive extracellular volume fraction [ECV] mapping), 11 more in-depth insights can be obtained into the pathophysiological processes such as the evolution of myocardial edema in the first week after STEMI, 12, 13 the chronic manifestation of intramyocardial hemorrhage, its prognostic significance over microvascular obstruction 14, 15 and changes in the remote myocardial interstitial space in those developing adverse LV remodeling 16, 17 after STEMI. In this article, we provide an overview of some of the recent advances in CMR imaging in reperfused patients with STEMI, discuss the recent controversies surrounding its use, and explore future applications of CMR in this setting.
BASIC CONCEPTS
In this section, we provide a brief description of some of the basic concepts concerning the use of CMR in STEMI. The Table provides an explanation of the more technical terms used throughout this article. Figure 1A also provides an illustration of the various components of the myocardium that can be interrogated by CMR.
MI Size
MI size refers to the infarcted myocardium and is conventionally quantified by late gadolinium enhancement (Table  and Figure 1B) . 36 The gadolinium chelate cannot cross the intact cell membranes. 36 After acute myocardial necrosis, the cell membranes are ruptured, allowing the contrast agent to enter these cells. In the chronic setting, there is also expansion of the extracellular space caused by collagen deposits and the relatively low residual amount of intact cardiomyocytes in the region of the infarct. Therefore, after gadolinium chelate administration, the contrast redistributes itself from the vascular compartment to the interstitial space, and at pseudoequilibrium, a higher concentration of contrast is distributed in areas of acute or chronic MI than in normal myocardium 9 (Table) .
Microvascular Obstruction and Intramyocardial Hemorrhage
Microvascular obstruction refers to the inability to reperfuse the coronary microcirculation in a previously ischemic region, despite opening of the epicardial vessel. 37 Microvascular obstruction can be identified as a dark hypointense core within the areas of hyperenhancement on either early gadolinium enhancement (referred to as early microvascular obstruction) or conventional late gadolinium enhancement (referred to as late microvascular obstruction) sequences, defined in the Table and illustrated in Figure 1B .
If the coronary microvasculature injury after STEMI is especially severe and the integrity of the vessels is compromised, extravasation of red blood cells into the myocardium can occur, which is called intramyocardial hemorrhage. 14 The breakdown products of hemoglobin within the myocardium can be detected as a hypointense core 38 within the MI zone on T2* imaging or T2* mapping (Figures 1 and 2 ). Of the 2 approaches, T2* mapping has been shown to have greater sensitivity for detecting intramyocardial hemorrhage after STEMI compared with T2 mapping (Table) . 21, 39 A small study previously showed that the hypointense core on the T1 or T2 maps could provide an alternative method to detect intramyocardial hemorrhage in cases when T2* is not available or not interpretable (Figures 1 and 2) . 38 Further studies are needed to confirm these findings.
Area at Risk
The area at risk refers to the territory supplied by the infarct-related artery that would have infarcted after STEMI if reperfusion had not taken place to salvage viable myocardium. The area at risk includes both the reversibly-injured myocardium (also referred to as the salvaged myocardium) and the infarcted myocardium. Figure 3 shows an example of the edema-based area at risk by T1 and T2 mapping and the corresponding MI size on late gadolinium enhancement in a patient presenting with an acute inferior STEMI treated by PPCI.
A number of CMR approaches to delineating the area at risk after STEMI have been described (Table) . However, they all have their limitations, 40 and although each technique has been validated against histology in the preclinical setting, 23, 26, 29, 30, 32 there is currently no consensus on which CMR method should be used to quantify the area at risk in the clinical setting. So far, no studies have compared these techniques head to head in the same patient cohort. Once the area at risk and MI size are known, the myocardial salvage index can be calculated as described in the Table. The myocardial salvage index is considered a more sensitive measure for assessing the efficacy of novel cardioprotective therapies compared with MI size alone 34 because it normalizes the MI size reduction to the area at risk, the latter of which varies from patient to patient. Therefore, the myocardial salvage index may help to reduce the sample size for clinical cardioprotection studies compared with using MI size alone.
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RECENT ADVANCES IN THE ROLE OF CMR IN REPERFUSED PATIENTS WITH STEMI
In this section, we elaborate on how CMR has improved our understanding of the relationship between microvascular obstruction and intramyocardial hemorrhage, as well as the role of MI size, intramyocardial hemorrhage, residual myocardial iron, and the remote myocardium in the development of adverse LV remodeling. Finally, we explore the prognostic significance of these CMR-derived indexes in reperfused patients with STEMI.
STATE OF THE ART
T1 Mapping for the Quantification of MI Size
Postcontrast T1 mapping has recently emerged as a promising technique for the quantification of MI size as an alternative to conventional late gadolinium enhancement imaging. Bulluck and colleagues 41 recently showed that postcontrast T1 mapping can accurately quantify acute MI size in a small group of patients with STEMI, obviating the need to perform late gadolinium enhancement imaging. Recent studies have also investigated whether native T1 mapping (precontrast) can assess MI size. Kali and colleagues 42 showed that chronic MI (median of 13.6 years after MI) could be detected with native T1 mapping at 3 T in a small cohort of 25 patients. Liu and colleagues 43 showed that native T1 mapping at 3 T could also identify acute MI size. How- This is the time constant to recover 63% of its longitudinal magnetization (spin-lattice relaxation) and is expressed in milliseconds. It is referred to as native T1 when performed before the administration of gadolinium chelate.
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It is recommended that postcontrast T1 be performed at least 10 min after contrast administration.
Once the native and postcontrast T1 of the blood and myocardium and the hematocrit are known, the ECV can be calculated with this formula 11 : ECV (%)=(100−hematocrit)×(1/postcontrast T1 myocardium )−(1/native T1 myocardium )
(1/postcontrast T1 blood )−(1/native T1 blood )
T2
This refers to the constant representing the decay of transverse magnetization (spin-spin relaxation) to 37% of its initial equilibrium value and is expressed in milliseconds.
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T2* This is the time constant representing the decay of transverse magnetization in the presence of local magnetic field inhomogeneities and is expressed in milliseconds.
Parametric mapping This is a process whereby an anatomic map is generated with each pixel representing a specific magnetic tissue property (T1, T2, or T2* or ECV) derived from the spatially corresponding voxel of a set of coregistered magnetic resonance source images.
MI size This refers to the mass or volume of infarcted myocardium and is conventionally quantified by late gadolinium enhancement.
After 10 min, pseudoequilibrium of gadolinium chelate concentration between blood and well-perfused myocardium develops. During this time, a higher concentration of contrast is distributed in areas of acute or chronic MI (significantly shortening T1) than in normal myocardium. Therefore, with appropriate nulling of the remote myocardium with inversion recovery T1-weighted sequences, the necrotic or scarred areas appear bright. 6, 9 Early microvascular obstruction This can be identified as areas of dark core within the MI zone with first-pass perfusion or EGE imaging performed with a fixed, high TI (eg, 440 to 500 ms at 1.5 T) acquired at 1-4 min after contrast injection.
Late microvascular obstruction This can be identified as a dark core within the areas of hyperenhancement on conventional late gadolinium enhancement sequences acquired >10 min after contrast injection.
Intramyocardial hemorrhage This can be identified with T2* -weighted imaging or T2* mapping.
From brain imaging data, the degradation of the extravasated erythrocytes to oxyhemoglobin, deoxyhemoglobin, and methemoglobin (strongly paramagnetic) is dynamic and exhibits different magnetic properties at various stages, as previously described by Bradley. 18 Breakdown of the erythrocyte membrane eventually leads to ferritin and hemosiderin deposits within the macrophages, and the iron-degradation products can be detected with T2* imaging.
Most studies have used a cutoff value for T2*of <20 ms 14, 19 to detect intramyocardial hemorrhage, but a threshold-based method of 2 SDs below the mean remote myocardial T2* can also be used. 20 In centers where T2* imaging is not available, many studies have also used T2-weighted imaging, but its diagnostic performance is less robust than T2*-weighted imaging. 21 
Area at risk
This refers to the territory supplied by the infarct-related artery and includes both the reversibly-injured myocardial (the salvaged myocardium) and the infarcted myocardium. The area at risk can be indirectly assessed by CMR with late gadolinium enhancement imaging (to derive the endocardial surface area), 22 T2-weighted imaging, 23, 24 T2 mapping, 25, 26 native T1 mapping, 26, 27 EGE imaging, 28, 29 precontrast SSFP cine, 30 and postcontrast SSFP cine imaging. 31, 32 T1 mapping and T2 mapping are currently considered the most robust of the CMR techniques because they have a better contrast-to-noise ratio than the T2-weighted/T1-weighted/cine imaging techniques, they are less prone to blood pool and motion artifacts, and they are less likely to have signal dropout resulting from surface coil inhomogeneities. 25, 27, 33 Myocardial salvage and myocardial salvage index Myocardial salvage can be calculated by subtracting the MI size from the area at risk.
The myocardial salvage index refers to the ratio of the myocardial salvage to the area at risk. 34 Remote myocardium This is usually defined as a myocardial segment 180° from the infarcted territory. 35 CMR indicates cardiovascular magnetic resonance; ECV, extracellular volume fraction; EGE, early gadolinium enhancement; MI, myocardial infarction; SSFP, steadystate free precession; and STEMI, ST-segment-elevation myocardial infarction. ever, only 58 short-axis T1 maps without microvascular obstruction were analyzed in that study. 43 These findings are of great interest because one could potentially perform a comprehensive CMR study in STEMI without the need of contrast agent, and this approach would significantly shorten the scan time and make CMR available to a wider range of patients.
Whether ECV on an acute CMR scan can estimate final MI size after STEMI has recently been investigated. Garg and colleagues 44 showed that an ECV value of ≥0.46 could predict chronic MI size from the acute ECV maps. However, Bland-Altman analysis showed a bias of 1.9% and wide limits of agreement of ±10.5%. Therefore, further studies are needed to build on these findings. 45 However, as it stands, ECV mapping may complement late gadolinium enhancement imaging to assess MI size and to predict wall motion recovery at follow-up, as recently shown by 2 small studies. 16 A, The various components of the myocardium in a reperfused patient with STEMI that can be assessed by cardiovascular magnetic resonance (CMR), namely the area at risk, salvaged myocardium, the area of hyperenhancement, and the hypointense core on late gadolinium enhancement (LGE) images and the remote myocardium. The MI size includes both the areas of hyperenhancement and the hypointense core on LGE images. The hypointense core on LGE represents microvascular obstruction (MVO), and a proportion of patients would also have intramyocardial hemorrhage (IMH) within these areas (areas of low T2* on T2*-weighted images or mapping). The area at risk is a combination of both the MI size and the salvaged myocardium. B, The CMR-based methods and their timing during CMR acquisition for delineating the area at risk, MI size, MVO (early and late), and IMH. The most robust method for demarcating the area at risk currently is T1 and T2 mapping. LGE is the gold standard for detecting MI size and late MVO. T2* mapping is currently the gold standard to detect IMH. The table provides an indication of the abilities of each sequence to detect each components of an MI by STEMI graded as follows:  indicates robust, ie, shown by several studies; , possible, ie, shown by some studies; and , theoretically possible and/or shown by 1 to 2 studies. EGE indicates early gadolinium enhancement; and ESA, endocardial surface area.
Despite the promises of T1 mapping in STEMI for measuring MI size, the published studies have been small and from single-centers. Larger studies are therefore required to confirm these findings using different field strengths, mapping sequences, and vendors before they can be more widely adopted.
Relationship Between Microvascular Obstruction and Intramyocardial Hemorrhage
Serial CMR imaging of patients with STEMI in the first few days after PPCI has provided evidence that the incidence and extent of microvascular obstruction and intramyocardial hemorrhage vary with time. The extent of late microvascular obstruction has been reported to peak at 4 to 12 hours, to remain stable the first 2 days, and to reduce in size by day 10 after STEMI.
14 Furthermore, in those patients with microvascular obstruction persisting at 1 week, Ørn and colleagues 47 showed that they were more likely to develop adverse LV remodeling compared with those with microvascular obstruction at day 2 only. On the other hand, the detection of intramyocardial hemorrhage has been shown to peak at day 3 and to reduce in incidence by day 10 after PPCI. 12 Hamirani and colleagues 39 showed that intramyocardial hemorrhage (detected by either T2-weighted imaging or T2* imaging) was more strongly associated with late microvascular obstruction (R=0.89-0.93) than with early microvascular obstruction (R=0.30). Using the more robust method of T2* mapping for the detection of intramyocardial hemorrhage, Carrick and colleagues 14 showed in 286 patients that all patients with intramyocardial hemorrhage also had late microvascular obstruction.
From these recent studies, 14, 39, 48, 49 it appears that early microvascular obstruction occurs in ≈60% to 65%, late microvascular obstruction in ≈50% to 55%, and intramyocardial hemorrhage in ≈35% to 40% of reperfused patients with STEMI. However, the detection of microvascular obstruction and intramyocardial hemorrhage is dependent on the CMR techniques, the timing of imaging, and the definitions used.
Acute MI Size and Subsequent Adverse LV Remodeling
Conventional theory assumes that the larger the MI, the higher the LV wall stress, and the LV therefore dilates to maintain the stroke volume as a compensatory mechanism (via the Frank-Starling principle). However, LV dilation, as described by the Laplace relationship, leads to further wall stress and begets more LV dilatation in the absence of compensatory LV hypertrophy. Westman and colleagues 50 have recently proposed that there is an imperfect association between MI size and adverse LV remodeling. They showed in 122 patients with STEMI that 15% of those with an MI <18.5% developed adverse LV remodeling and that 40% of those with an MI ≥18.5% developed adverse LV remodeling. However, Westman and colleagues 50 used a definition of >10-mL/m 2 increase in indexed LV end-diastolic volume in their study. A more appropriate definition for adverse LV remodeling after STEMI by CMR may be a cutoff value of a 12% change in LV end-diastolic volume. 51 This study also showed an imperfect association between acute MI size and adverse LV remodeling and between the presence of microvascular obstruction and adverse LV remodeling. 51 Some patients with a large MI and microvascular obstruction developed reverse LV remodeling, whereas other patients with a small MI and no microvascular obstruction also developed adverse LV remodeling. 51 As alluded to by Westman and colleagues, 50 the development of adverse LV remodeling is complex and multifactorial, and an excessive inflammatory response together with MI size may play an important role after STEMI. 
Residual Myocardial Iron and Adverse LV Remodeling
There are emerging data that intramyocardial hemorrhage at the time of PPCI leads to residual myocardial iron during the convalescent phase, and it may be a source of prolonged inflammation and have an impact on adverse LV remodeling. 52 Kali and colleagues 52 showed in a small cohort of 15 patients with STEMI and in 20 canines (with histological validation) that intramyocardial hemorrhage resulted in residual myocardial iron within the MI zone, and this provided a source of prolonged inflammatory burden in the chronic phase. These findings were recently confirmed in a canine model of MI, and the extent of residual iron was strongly correlated with markers of inflammation and adverse LV remodeling. 53 Roghi and colleagues 54 found higher levels of non-transferrin-bound iron in 7 of 15 patients with STEMI with microvascular obstruction and postulated that intramyocardial hemorrhage could be a source of cardiotoxicity in these patients.
In a small cohort of patients with STEMI, Bulluck and colleagues 15 recently found that intramyocardial hemorrhage and subsequent residual myocardial iron at follow-up were associated with persistently elevated T2 values in the surrounding infarct tissue and with adverse LV remodeling. 15 Carberry and colleagues 55 have recently confirmed these findings in a cohort of 203 patients with STEMI. They showed that 36% of their cohort had intramyocardial hemorrhage by T2* mapping and 59% of those had residual myocardial iron at 6 months. Residual myocardial iron was associated with adverse LV remodeling at 6 months and worse clinical outcomes after a median follow-up of 4 years. 55 Figure 4A shows an example of a patient with an acute inferior STEMI treated by PPCI and with late microvascular obstruction and intramyocardial hemorrhage despite restoration of normal flow in the epicardial coronary artery during PPCI. At follow-up, there was residual myocardial iron and persistently elevated T2 values in the areas surrounding the residual iron, which may represent persistent myocardial inflammation. Top, An example of the edema-based area at risk by T1 and T2 mapping (indicated by black arrows) and the corresponding MI size on LGE (red arrow) in a patient with an inferior ST-segment-elevation MI treated by primary percutaneous coronary intervention, with the cardiovascular magnetic resonance (CMR) images acquired on day 3 after reperfusion. Bottom, The corresponding postprocess images using a threshold-based method to delineate the area at risk (threshold of 2 SDs) and MI size (threshold of 5 SDs) as the highlighted areas with the areas of hypointense core included as part of the area at risk and MI size. The myocardial salvage (area at risk subtract the MI size) and myocardial salvage index (myocardial salvage as a ratio of the area at risk) can be calculated retrospectively from a single CMR scan. 
STATE OF THE ART
The Role of the Remote Myocardium and Clinical Outcomes
Whether changes in the extracellular matrix in the remote myocardium (Table) in patients with STEMI treated by PPCI are associated with adverse LV remodeling has been a topic of ongoing research. 16, 17, [56] [57] [58] Using automated ECV maps, Bulluck and colleagues 16 have shown in a small cohort of 40 patients with STEMI that ECV in the remote myocardium was acutely elevated and that this elevation in ECV persisted in those who developed adverse LV remodeling at 5 months, suggesting that remote compensatory changes in the extracellular matrix occurred in this subset of patients. The increase in acute ECV could have been due to an increase in the intravascular compartment as a compensatory mechanism. At follow-up, the increase in ECV likely represented diffused interstitial fibrosis as part of the remodeling process. Garg and colleagues 58 recently confirmed these findings in a cohort of 50 patients with STEMI. Furthermore, they also showed that remote segments with ECV expansion were associated with impaired wall thickening. In a larger cohort of patients (n=131), Carberry and colleagues 17 showed that the change in ECV of the remote myocardium was a multivariable associated with the change in LV end-diastolic volume at 6 months. Whether this change in ECV could independently predict those at risk of adverse events remains to be tested in future, adequately powered studies. Figure 4B shows an example of the paired acute and follow-up (6 months) late gadolinium enhancement and automated ECV maps with representative regions of interest of the remote myocardium of a patient with an anterior STEMI treated by PPCI.
Carrick and colleagues 57 demonstrated that higher native T1 of the remote myocardium of 267 reperfused patients with STEMI on the acute CMR scan was associated with changes in LV end-diastolic volume from baseline to 6 months, and it was independently associated with adverse cardiac events after a median follow-up of 845 days. Most recently, in a similar number of patients, Reinstadler and colleagues 56 also showed that the remote native myocardial T1 was independently associated with adverse events after adjusting for clinical risk factors and other CMR variables after a follow-up of 6 months.
Therefore, T1 mapping has the potential to complement clinical and other CMR-derived parameters to improve the risk stratification of patients with STEMI and warrants further investigation in a multicenter setting.
Acute MI Size and Clinical Outcomes
Morbidity and mortality after STEMI are closely related to acute MI size. A recent meta-analysis of 2632 patients showed that MI size measured by CMR or Shown is an example of the paired acute and follow-up (6 months) late gadolinium enhancement (LGE) and automated ECV maps and T2* and T2 maps of a patient with an inferior STEMI, treated by primary percutaneous coronary intervention with restoration of normal flow in the infarct-related epicardial coronary artery. The arrows show the area of microvascular obstruction with intramyocardial hemorrhage. The corresponding ECV maps show the area of microvascular obstruction where contrast fails to penetrate the areas of microvascular obstruction and appears as pseudonormal myocardium on the acute scan. At follow-up, the microvascular obstruction has resolved, and the space previously occupied by the microvascular obstruction has very high ECV (white areas within the MI zone corresponding to the upper limit of the look-up color scale). The white regions of interest on the ECV maps (black arrows) are representative areas of the remote myocardium that can be used to assess changes in the extracellular matrix. There were residual myocardial iron at follow-up and persistently elevated T2 in the areas surrounding the residual iron (blue arrows on the follow-up images).
single-photon emission computed tomography within a month after PPCI from 10 randomized controlled trials was strongly associated with 1-year hospitalization for heart failure and all-cause mortality. 59 For every 5% increase in MI size, there was a 20% increase in the relative hazard ratio for 1-year hospitalization for heart failure and all-cause mortality. The event rate was 1.2% in those with an MI ≤8% of the LV, and there was a stepwise increase to 2.5% in those with an MI >8% to ≤17.9% of the LV, 5.6% in those with an MI >17.9% to 29.8% of the LV, and 8.8% in those with an MI >29.8% of the LV. This study adds to the growing body of evidence that acute MI size is prognostic and therefore remains a valid surrogate end point for clinical trials. However, this study also highlights the fact that one of the limitations of using CMR in randomized controlled trials is that there is an element of selection bias because only those patients fit enough to tolerate a CMR study would enter these randomized controlled trials, and the overall event rates were 2.2% and 2.6% for allcause mortality and hospitalization for heart failure at 1 year, respectively, much lower than those reported from clinical registries.
2,3
Microvascular Obstruction, Intramyocardial Hemorrhage, and Clinical Outcomes
Both microvascular obstruction and intramyocardial hemorrhage are associated with larger MI size, adverse LV remodeling, and worse clinical outcomes. 39, 48 In a meta-analysis of >1000 patients, Van Kranenburg and colleagues 48 showed that the presence of microvascular obstruction was an independent predictor of major adverse clinical outcome at 2 years in patients with STEMI, whereas MI size was not independently associated with adverse events. There was a graded reduction in event-free survival in patients with an MI <25% of the LV with and without microvascular obstruction and those with an MI >25% of the LV with and without microvascular obstruction. The prognostic value of microvascular obstruction over MI size for mortality and hospitalization for heart failure was recently confirmed by de Waha and colleagues 49 in a pooled analysis of patient-level data from 7 randomized controlled trials (n=1688) at 1 year and by Symons and colleagues 60 in a longitudinal study of 810 patients after a median follow-up of 5.5 years.
Early studies showed that intramyocardial hemorrhage, detected by T2-weighted images, was closely related to the development of adverse LV remodeling and worse clinical outcomes. 39 Most recently, using T2* mapping, Carrick and colleagues 14 showed that intramyocardial hemorrhage was more closely associated with adverse clinical outcomes than microvascular obstruction.
Therefore, on the basis of the current evidence discussed so far, the prognosis worsens with a larger MI. Patients with a larger MI are also more likely to have microvascular obstruction and intramyocardial hemorrhage. The prognosis is worse for patients with STEMI with microvascular obstruction compared with those without microvascular obstruction 61 and is worst for those with microvascular obstruction and intramyocardial hemorrhage. 14 Currently, there are no effective methods to detect those at risk of microvascular obstruction and intramyocardial hemorrhage at the time of PPCI. Amier and colleagues 62 recently showed that anterior STEMI and the use of glycoprotein IIb/IIIa inhibitors were associated with the development of intramyocardial hemorrhage. However, this was a retrospective post hoc analysis, and intramyocardial hemorrhage was identified with T2-weighted imaging instead of the more robust T2*-weighted imaging, and their findings need to be confirmed in future studies. Furthermore, there are no established therapies to prevent or minimize the burden of microvascular obstruction and intramyocardial hemorrhage in the clinical setting, 4 although promising results are emerging in the preclinical setting.
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CURRENT CONTROVERSIES IN CMR IMAGING OF PATIENTS WITH STEMI Is Myocardial Edema Confined to the Infarct Zone, or Does It Extend Into the Salvaged Myocardium?
In the 1980s, Higgins and colleagues 64 were the first to study myocardial T2 CMR in a canine model of MI. Both T2 and T1 were shown to change similarly in the setting of an acute MI. The observed changes were theoretically consistent with myocardial edema and correlated with the measurements of myocardial water content estimated by wet weight to dry weight ratios. The changes in myocardial T2 have been attributed to a combination of an increase in absolute tissue water, the movement of water from the extracellular to the intracellular compartment, and the conversion of proteinbound water to free water. 65 Not all experimental and clinical studies have supported the concept that the region of hyperintensity on T2-weighted images delineates the area at risk. Aletras and colleagues 25 and Tilak and colleagues 66 validated the edema-based area at risk using T2-weighted images against microspheres in reperfused and nonreperfused canine MI. Ubachs and colleagues 67 showed that the area at risk derived from T2-weighted imaging matched that obtained from single-photon emission computed tomography in animals both with and without late gadolinium enhancement. In contrast, Kim and colleagues 68 reported that T2-weighted imaging did not depict the area at risk in anesthetized dogs that were subjected to different durations of coronary occlusion. MI size by late gadolinium enhancement was compared with the gold standard method of triphenyltetrazolium chloride staining, and area at risk by T2-weighted imaging was compared with the gold standard method of fluorescent microspheres 4 days after reperfusion. The T2-weighted hyperintensity correlated and matched in shape better with the MI size than with the area at risk, and these findings were confirmed in a small group of patients with acute MI. Although the findings from the canine model of MI may have resulted from the presence of well-developed collaterals in that species, the T2-weighted sequence in that study was different from that used so far by other studies. 23, 66 In the clinical setting, using hybrid positron emission tomography/CMR imaging in reperfused patients with STEMI, Bulluck and colleagues 69 recently showed that the area of reduced 18 F-fluorodeoxyglucose uptake was significantly larger than the MI size and closely matched the area at risk delineated by T2 mapping on the acute scan, supporting the notion that T2-mapping delineates both the reversibly and the irreversibly injured myocardium within the area at risk. 69 In addition, the areas of reduced 18 F-fluorodeoxyglucose uptake within the salvaged myocardium in the area at risk were no longer present on a follow-up scan several months later. 69 Hammer-Hansen and colleagues 70 have provided further insights into this topic using a canine model of MI. They showed that T2 values were elevated in both the MI zone and salvaged myocardium, and they were both significantly higher than the T2 values in the remote myocardium.
STATE OF THE ART
Therefore, the majority of the current literature supports the notion that edema, assessed by CMR with T2 mapping, occurs in both the irreversibly and reversibly injured myocardium during the first week of a reperfused STEMI in the clinical setting. 25, 27, 69, 71 
Dynamic Changes in the Edema-Based Area at Risk During the First Week in Reperfused Patients With STEMI
It was initially believed that edema is stable in the first week of an MI. 71, 72 However, both of these studies performed T2-weighted imaging only on days 1 and 7, and the peak in the edema-based area at risk shown by Carrick and colleagues12 on day 3 was therefore not identified by the previous 2 studies. 71 Emerging evidence suggests that the extent of myocardial edema is dynamic. Hammer-Hansen and colleagues 70 have shown in a canine model of reperfused MI that at 2 hours T2 values were higher in both the infarcted and salvaged myocardium compared with those who had the scan at 48 hours, highlighting that the extent of myocardial edema within the first few days of an MI is dynamic.
Fernández-Jiménez and colleagues 73 studied the interplay between myocardial water content (using desiccation) and T2 relaxation times in a porcine model of reperfused MI. They reported a "bimodal" pattern of edema, appearing at 2 hours, resolving by 24 hours, and then reappearing on day 4 and peaking at day 7. The first wave of edema was attributed to myocardial reperfusion injury, and the second wave of edema was attributed to inflammation during the tissue-healing phase. 74 However, they did not take into account the presence of microvascular obstruction and intramyocardial hemorrhage, which may have interfered with their T2 measurements, and they had a small sample size of 5 pigs at each time point. Furthermore, the same animals were not serially scanned. Most recently, Fernán-dez-Jiménez and colleagues 13 showed that the bimodal edematous response of the infarct-related territory also was present in humans. However, they used the less robust T2-weighted imaging modality instead for both quantifying the extent of the edema-based area at risk and for detecting intramyocardial hemorrhage. It was not clear how many of their 14 patients had intramyocardial hemorrhage in that cohort. Furthermore, on a patient-level basis (their supplementary material Figures  3 and 4) , not all patients displayed a bimodal response for the intensity and extent of edema in the infarctrelated territory.
In contrast to these studies, in a cohort of 30 patients with serial imaging, Carrick and colleagues 12 found that the extent of myocardial edema was maximal at day 3 and decreased by day 10 after PPCI, suggesting a unimodal peak in myocardial edema in the first few days after reperfusion. In patients with STEMI with intramyocardial hemorrhage, they observed a bimodal pattern in T2 and T2* values within the MI core, whereas in patients without intramyocardial hemorrhage, only a unimodal pattern in T2 and T2* values was observed, suggesting that the presence of intramyocardial hemorrhage may have been responsible for the apparent bimodal edema pattern in T2 and T2* values.
Nordlund and colleagues 31 recently provided some evidence that there was no bimodal pattern of edema in the clinical setting. They combined data from 3 studies involving 215 patients and showed that there were no differences in size, quality of the T2-weighted images, and the ability to detect the culprit territory when patients having a CMR study on day 1 to 6 onward were compared.
Given the dynamic changes in the extent of edema and acute MI size over the first few days after STEMI, it is important that future clinical cardioprotection studies define the time window for performing the acute CMR scan to optimize the quantification of both acute MI size and area at risk. There is currently no consensus on the optimal timing for performing the acute CMR scan, although 3 to 5 days 6 and 4 to 7 days 13 after PPCI have been proposed.
Cardioprotective Therapies and the Edema-Based Area at Risk in Reperfused Patients With STEMI
The utility of T2-weighted imaging for quantifying the area at risk has been called into question because certain cardioprotective therapies have been shown to reduce not only MI size but also the extent of myocardial edema measured by T2-weighted and T2-mapping imaging. Ischemic postconditioning 75 and remote ischemic conditioning using transient arm or leg ischemia and reperfusion 76 have been shown to reduce both MI size and the extent of edema delineated by T2-mapping and T2-weighted imaging, leading to an underestimation of the area at risk by these techniques. However, these were small studies of reperfused patients with STEMI, and they were not adequately powered to assess that end point. Intuitively, if a cardioprotective therapy can reduce MI size, it should be expected to also limit the extent of myocardial edema, which itself is the result of myocardial ischemia and reperfusion injury.
However, in a recently published large study of 696 patients with STEMI by Eitel and colleagues, 77 ischemic postconditioning or a combination of remote ischemic conditioning and ischemic postconditioning did not reduce the extent of myocardial edema compared with the control arm. Furthermore, drugs such as metoprolol 78 and exenatide 79 that were effective at increasing the myocardial salvage index did not reduce the extent of myocardial edema. One potential explanation for this discrepancy could be that those therapies that are potent enough to reduce MI size in reperfused patients with STEMI are capable of reducing the extent of myocardial edema. In contrast, those therapies that are less potent, do not reduce MI size, and only increase myocardial salvage do not affect the extent of myocardial edema. Either way, these findings may bring into question the use of edema-based area at risk measured by CMR to assess myocardial salvage in clinical cardioprotection studies.
The Optimal Timing of Late Gadolinium Enhancement Imaging for Acute and Chronic MI Size Quantification
Acute MI size has been shown to be dynamic and to decrease significantly in size between days 1 and 7 after STEMI. 80 In a recent study by Carrick and colleagues, 12 MI size was shown to be similar between days 1 and 3 and reduced by day 10. Jablonowski and colleagues 81 recently provided some mechanistic insights into this phenomenon in a porcine model of acute MI. At day 1, they found higher ECV values in the peri-infarct zone that could have been the result of severe edema or a mixture of infarcted and salvaged myocardium in that area that contributed to the overestimation of MI size. By 7 days, the ECV values in the peri-infarct zone decreased to the same level as the rest of the salvaged myocardium, such that MI size assessed by late gadolinium enhancement matched that by histology. Acquiring late gadolinium enhancement too early (<8 minutes after contrast administration) can result in an overestimation of MI size, 82 and acquiring late gadolinium enhancement at 25 minutes for acute MI size has been shown to be a better predictor of LV recovery. 83 However, waiting 25 minutes after contrast administration may be difficult in the clinical setting because of time constraints and would affect workflow. Therefore, late gadolinium enhancement images are currently acquired 10 to 15 minutes after contrast 6 as a compromise.
Several studies have already shown a significant regression in MI size (by 30%-35%) occurring between the acute CMR scan and the chronic phase. 47, 84, 85 Several factors are responsible for this observation. First, the compositions of the different tissues being identified by late gadolinium enhancement in the acute (myocardial necrosis compounded with edema, intramyocardial hemorrhage, and microvascular obstruction) and chronic (focal replacement fibrosis) phase are different. The regression of MI size between the acute, subacute and chronic phases therefore represents the gradual resolution of edema, intramyocardial hemorrhage, and microvascular obstruction and the gradual replacement of the necrotic cardiomyocytes with focal scars. 71, 85 As it stands, the optimal timing of CMR for MI size is not well established, but late gadolinium enhancement appears to stabilize by 10 days after the index event. 12 In most centers, patients with STEMI with an uncomplicated inpatient stay are discharged within the first week. Logistically, this would mean that patients would have to come back for the CMR scan, and this may lead to a proportion of patients dropping out. 6 Efforts are underway to attempt to standardize the acquisition of CMR for clinical cardioprotection studies. used as surrogate end points for randomized controlled trials assessing the effectiveness of new cardioprotective therapies and can reduce the sample size required. 6 However, acute MI size is influenced by a number of factors, including the timing of the CMR scan, the dose of contrast used, the time elapsed after contrast administration and acquisition of late gadolinium enhancement imaging, and the method used for the quantification of MI size. 6, 89 Therefore, there is an urgent need for the CMR community to come up with a consensus statement to standardize the acquisition of late gadolinium enhancement imaging and the quantification of MI size in future studies. 6 This would no doubt help to strengthen the robustness of this technique and would facilitate prospective or retrospective collaborative research with merging of CMR data from different centers around the world.
Toward Improving the Tolerability and Accessibility of CMR in Reperfused Patients With STEMI
There have already been some advances in free-breathing and motion-corrected T2 90 and T2* mapping 91 and late gadolinium enhancement imaging, 92 negating the need for breath-holding and helping to accelerate the acquisition of these sequences. Other developments in real-time cine imaging for LV ejection fraction and future refinements in CMR fingerprinting techniques (for robust and fast acquisition of simultaneous T1 and T2 mapping data per slice within 1 breath-hold) will further reduce scan time and will be highly desirable in the acute STEMI setting. These developments would make CMR, which is currently confined to those fit enough to lie inside the scanner for at least 30 to 45 minutes, accessible to a wider number of patients. Furthermore, reducing the duration of the scan to 20 to 30 minutes could also potentially reduce the cost of a scan and improve the participation of more centers in STEMIrelated CMR research. However, most of these new developments are still in the validation phase and are not available to all CMR vendors and platforms.
The use of gadolinium chelates is not recommended in those with a glomerular filtration rate <30 mL·min , to minimize the risk of nephrogenic systemic fibrosis, and constitutes a contraindication in CMR-based clinical cardioprotection studies. Furthermore, the US Food and Drug Administration has recently issued a new warning about gadolinium remaining in a patient's brainstem for months to years after receiving these drugs. However, gadolinium retention has not been directly linked to adverse events in patients with normal renal function, and the current benefits of using gadolinium chelates outweigh any potential risks. Therefore, the potential for noncontrast CMR imaging such as T1 mapping 19 and T2* mapping 14 to provide adequate prognostic information over postcontrast imaging modalities and to be applied to all patients, regardless of renal function, warrants further investigation.
CMR as a Tool to Risk Stratify and Guide Management in Patients With STEMI at Risk of Developing Adverse LV Remodeling and Subsequent Heart Failure
A number of cardioprotective therapies have had promising results in the experimental setting for reducing MI size and preventing adverse LV remodeling but have failed to be translated into the clinical setting. 93 A more targeted approach using CMR to identify those most at risk (eg, according to their acute MI size or according to the presence or absence of microvascular obstruction) may improve the translation of those promising experimental results in the clinical setting to prevent adverse LV remodeling and reduce the onset of heart failure in these patients. Stiermaier and colleagues 94 and Pontone and colleagues 95 most recently proposed CMR risk scores to identify those at high risk of adverse events. Their approach would be ideal to identify high-risk patients, but the CMR indexes and cutoff values included in each study differed, and further validation work is required to build on their findings. Furthermore, CMR could identify those with intramyocardial hemorrhage, and they could be targeted with anti-inflammatory agents or chelation therapy 15, 96 to minimize the cardiotoxic effects of the residual iron (which has been shown to occur in two third of patients with intramyocardial hemorrhage from a pooled analysis of 4 studies) 55 during the convalescent phase of an acute STEMI. This warrants further investigation.
CMR as a Tool for Risk Stratification of Patients With STEMI at Risk of Arrhythmic Events
The current guidelines recommend an implantable cardioverter-defibrillator for primary prevention in those with symptomatic heart failure and LV ejection fraction <35% 40 days after the index event. 97 However, mortality within the first 30 days after MI has been shown to be the highest 98 but is believed to be predominantly the result of MI or myocardial rupture. 99 Despite that, a quarter of those deaths are still caused by ventricular arrhythmias, 99 and there currently is no established tool to risk stratify these patients in the acute phase of an MI. Acute MI size (cutoff of 23.5 g/m 2 or 31% of the LV) in combination with LV ejection fraction (cutoff of 36%) by CMR within the first week after an MI has been shown to predict adverse arrhythmic cardiac events at 2 years. 100 Other studies have shown that CMR in the chronic phase could also be used to predict sudden cardiac death with the use of the peri-infarct zone extent 101 or chronic MI size 102 in combination with LV ejection fraction. Furthermore, residual myocardial iron as a consequence of intramyocardial hemorrhage has also been shown to be proarrhythmic. 103 Although all of these were relatively small and single-center studies, CMR has shown promise to improve the risk stratification of patients with STEMI at risk of ventricular arrhythmias. With the availability of inline, automated ECV mapping 104 and free-breathing T2* mapping, 91 characterization of the infarct size, peri-infarct zone, and infarct core may become more objective, and CMR would play an invaluable role in identifying those most likely to benefit from a primary prevention implantable cardioverter-defibrillator in the near future.
CONCLUSIONS
Over the last few years, CMR scans performed in the acute phase of reperfused STEMI have improved our understanding of the changes occurring in the infarcted, salvaged, and remote myocardium and have provided insights into the impact of MI size, microvascular obstruction, and intramyocardial hemorrhage on clinical outcomes. There are ongoing controversies surrounding the use of CMR to delineate the area at risk and the dynamic changes in myocardial edema in the first few days after PPCI. However, more work is ongoing, and CMR holds promise to become accessible to more patients and to be used as a tool to risk stratify patients, to guide treatment, and to improve clinical outcomes after PPCI in the near future. 
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